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Abstract
Background: Over 300 therapies have been proposed for premenstrual syndrome. To date there
has been only one survey conducted in the UK of PMS treatments prescribed by GPs, a
questionnaire-based study by the National Association of Premenstrual Syndrome in 1989. Since
then, selective serotonin re-uptake inhibitors have been licensed for severe PMS/PMDD, and
governmental recommendations to reduce the dosage of vitamin B6 (the first choice over-the-
counter treatment for many women with PMS) have been made. This study investigates the annual
rates of diagnoses and prescribing patterns for premenstrual syndrome (1993–1998) within a
computerised general practitioner database.
Methods: Retrospective survey of prescribing data for premenstrual syndrome between 1993–
1998 using the General Practice Research Database for the West Midlands Region which contains
information on 282,600 female patients
Results: Overall the proportion of women with a prescription-linked diagnosis of premenstrual
syndrome has halved over the five years. Progestogens including progesterone were the most
commonly recorded treatment for premenstrual syndrome during the whole study period
accounting for over 40% of all prescriptions. Selective serotonin-reuptake inhibitors accounted for
only 2% of the prescriptions in 1993 but rose to over 16% by 1998, becoming the second most
commonly recorded treatment. Vitamin B6 accounted for 22% of the prescriptions in 1993 but
dropped markedly between 1997 and 1998 to 11%.
Conclusions: This study shows a yearly decrease in the number of prescriptions linked to
diagnoses for premenstrual syndrome. Progestogens including progesterone, is the most widely
prescribed treatment for premenstrual syndrome despite the lack of evidence demonstrating their
efficacy.
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Background
It is estimated that between 85% to 97% of women of re-
productive age experience some symptoms in the premen-
strual phase of the cycle and about 30–40% of these
women will seek help from their GP [1]. Premenstrual
syndrome is defined as the recurrence of adverse physical
and behavioural symptoms which recur in the luteal
phase and which remit during, or after, menstruation; the
symptoms are severe enough to significantly disrupt every
day life for 3–5% of women [2]. The underlying cause of
premenstrual syndrome remains unclear and speculative;
many hypotheses have been suggested and numerous
treatments advanced. The uncertainty as to the aetiology
of premenstrual syndrome coupled with the very high pla-
cebo response has resulted in a large number of claims for
potential therapies. There have been as many as 327 dif-
ferent treatments for premenstrual syndrome [3]. The va-
riety of treatment approaches include hormonal
preparations (oestrogen, oral contraceptives, GnRH ana-
logues, danazol, progestogens and progesterone), diuret-
ics, antidepressants, nutritional therapies (vitamin B6,
mineral supplements and evening primrose oil), bromoc-
riptine, surgery, complementary therapy and more recent-
ly light therapy and psychotherapy (cognitive and
behavioural therapy) [4].
Despite this wide range of possible therapies for premen-
strual syndrome no recent information concerning pre-
scribing habits for premenstrual syndrome has been
conducted in the UK. A survey of 658 women with self-re-
ported PMS by Corney and Stanton [5] in 1990 found that
vitamin B6 was the most widely used treatment, followed
by evening primrose oil and then hormonal preparations.
A similar survey of 220 women with self-reported PMS in
the US found that dietary supplements and exercise were
the most frequently suggested treatment option followed
by progesterone and pain relievers [1]. Another recent sur-
vey found that of the 31% of women who reported severe
premenstrual symptoms less than half sought any help for
their condition. One of the reasons given was the belief
that no effective treatments were available. Of those who
used prescription medicines, paracetamol, vitamin B6,
progesterone and oral contraceptives were the most fre-
quently used treatments in the UK [6].
However, whilst these studies provide valuable informa-
tion on what women are using to gain relief for their
symptoms this does not necessarily reflect what General
Practitioners are prescribing for this syndrome. A survey of
diagnostic and treatment practices of US and Canadian
primary care physicians reported in 1984 found that pro-
gesterone suppositories were the most widely prescribed
treatment; 70% of all the surveyed physicians prescribed
progesterone [7]. The National Association for Premen-
strual Syndrome in 1989 assessed the treatment practices
of 273 general practitioners in the UK by questionnaire.
They found that 68% of general practitioners reported
prescribing vitamin B6 and over half reported that they
prescribed progestogens or progesterone for premenstrual
symptoms [8].
In the last three years premenstrual syndrome has gained
considerable media attention. In 1997, the UK Depart-
ment of Health proposed to limit the sales of vitamin B6,
a very popular self-help remedy for premenstrual syn-
drome, because of possible neurotoxic side effects at high-
er doses [9]. In 1999, the Medicines Control Agency
granted the selective serotonin re-uptake inhibitor, fluox-
etine, a license for use in severe premenstrual syndrome/
premenstrual dysphoric disorder. This was the first time a
licence has been granted specifically for premenstrual dys-
phoric disorder. There has also been heavy media and In-
ternet promotion of 'natural' topical progesterone creams
for PMS [10].
One of the issues highlighted in the 1989 UK postal sur-
vey of general practitioners [8] was the wide variety of
treatments used by GPs to manage premenstrual syn-
drome. In order to determine current prescribing patterns,
we used the General Practitioner Research Database
(which records prescribing patterns and referrals) for the
years 1993–1998 to identify prescriptions associated with
the diagnosis of premenstrual syndrome.
Methods
The General Practitioner Research Database (GPRD) is an
UK database, which records prescribing data and referrals
and provides a valuable resource for analysing prescribing
patterns. Anonymised records of individual patients are
allocated a unique patient number. Data on medical
events, patient problems and other doctor-patient inter-
ventions are captured in the database through the OXMIS
(Oxford Medical Information System) dictionary. The
OXMIS dictionary is an amalgamation of the eighth revi-
sion of the International Classification of Diseases (ICD-8)
and the surgical operation codes used by the Office of Na-
tional Statistics. During 1998 some practices started using
Read codes. The Read codes were developed by James
Read in the early 1980s to enable GPs to code and record
relevant information from a patient encounter. Read
codes are cross-referenced to the main national and inter-
national classifications. General Practitioners who pro-
vide data for the database have agreed to record the
information in a standard manner to permit its use in re-
search. The General Practitioner Research Database for the
West Midlands former region contains 33 million records
for prescribing or diagnosis for a population of 612 700
patients. The age sex profile of the patients for the West
Midlands region matches that of England and Wales and
represents 10% of the UK population [11].BMC Women's Health 2002, 2 http://www.biomedcentral.com/1472-6874/2/4
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For individual patient records, a gynaecologist (PMSOB)
and a researcher (KW) reviewed the OXMIS and Read
codes to select the codes which define premenstrual syn-
drome. Table 1 details the General Practice Research Data-
base diagnoses used to identify premenstrual syndrome.
All diagnoses of premenstrual syndrome with same-day
prescriptions were extracted from the General Practice Re-
search Database.
Prescriptions were linked to diagnoses by patient identifi-
er, date of prescription and diagnosis. Prescription rates
for premenstrual syndrome were calculated for 1993–
1998 (the prescription rate is defined as the number of
prescriptions for a specific drug group linked to a diagno-
sis of premenstrual syndrome, divided by the total
number of prescriptions linked to diagnosis of premen-
strual syndrome for that year). Prescriptions were identi-
fied as either repeat or acute and were determined for each
drug group.
The Medicines Control Agency was contacted for a list of
drugs, which have been licensed for premenstrual syn-
drome, premenstrual tension, premenstrual mastalgia,
premenstrual oedema or premenstrual dysphoric disor-
der. The British National Formulary (BNF March 2001)
and Monthly Index of Medical Specialities (MIMS; Octo-
ber 2000) and the Compendium of Datasheets (1999–
2000) were searched for indicated treatments for the same
disorders. Any identified treatment indicated for premen-
strual symptoms was subsequently cross-checked in the
other publications.
Table 2: (see Additional File) shows the list of drugs which
have either been licensed for premenstrual symptoms or
which appear in the data sheet compendium, MIMS or the
BNF as indicated for premenstrual symptoms.
Statistical analysis
The yearly trends in prescribing for the individual drugs
were analysed using Armitage trend test, P < 0.05 was con-
sidered to be significant [12]. Armitages trend test is used
when one wishes to compare proportions between groups
where the groups are ordered, to establish whether there
is an upward or downward trend in the proportions. Here
the ordered groups are years and the data was analysed to
determine whether the proportion of prescriptions linked
to diagnoses of PMS is increasing or decreasing over time.
Results
A total of 5,891 women were diagnosed with premen-
strual syndrome between 1993–8 and issued with 6,172
same-day prescriptions. Table 23 shows the rate of diag-
nosis of premenstrual syndrome fell from 0.92% (of the
total female population in the West Midlands GPRD) in
1993 to 0.42% in 1998. The rate of prescribing fell from
1.01% to 0.67%. Prescribing fell for all the British Nation-
al Formulary sub-groups except selective serotonin re-
uptake inhibitors.
Table 1: GPRD diagnoses for PMS
OXMIS 6269a Tension premenstrual
6269f Syndrome premenstrual
6269mt Tension menstrual
READ k584.00 Premenstrual tension syndrome
k584.11 Migraine menstrual
Table 3: Rates of diagnosis of premenstrual syndrome
Year Number of diagnoses Number of same day 
prescriptions
Female population 
(GPRD)
% diagnoses % same day prescrip-
tions
93 1533 1688 166845 0.92 1.01
94 1231 1325 172003 0.72 0.77
95 1178 1230 182204 0.65 0.68
96 863 861 131226 0.66 0.66
97 645 667 121754 0.53 0.55
98 441 401 105571 0.42 0.38
93–98 5891 6172 879602 0.67 0.70BMC Women's Health 2002, 2 http://www.biomedcentral.com/1472-6874/2/4
Page 4 of 8
(page number not for citation purposes)
Figure 1 shows the rates of prescribing for the individual
drug groups for 1993–1998. There was a significant
downward trend (P < 0.05) in the prescription rates for vi-
tamin B6, progesterone and progestogens and gonado-
trophins and a significant upward trend over the study
period for selective serotonin reuptake inhibitors. During
the study period progestogens (including progesterone)
were the most widely prescribed treatment comprising
44% in 1993 and still accounted for 42% of all prescrip-
tions in 1998. There were significantly more prescriptions
for progesterone and progestogens over the five-year peri-
od than any other drug type (P < 0.05). The most marked
increase in prescriptions over the study period was for se-
lective serotonin reuptake inhibitors; they represented
only 2% of all prescriptions for premenstrual syndrome in
1993 but by 1998 accounted for 16% of all prescriptions.
Similarly, the most marked fall in prescriptions was for
prescriptions of vitamin B6 which fell from 22% in 1997
(the second most frequent prescription) to 11% in 1998.
Figure 2 shows a detailed yearly breakdown of the differ-
ent treatments, which make up the progestogen/proges-
terone category. There was a significant drop in the level
of prescriptions for progesterone (32% in 1993; 14% in
1998 of prescriptions in this category) and a correspond-
ing increase in the number of prescriptions for dydroges-
terone (19% in 1993; 40% in 1998). Prescriptions for
norethisterone remained nearly constant accounting for
approximately 45% of all progestogen and progesterone
prescriptions. There were very few prescriptions of me-
droxyprogesterone acetate for premenstrual syndrome
during this study period (1–4%). Of the progesterone pre-
scriptions all were for Cyclogest® which is progesterone
administered as a suppository or pessary. There were no
recorded prescriptions for Crinone®, the vaginal proges-
terone gel or for Gestone® (progesterone administered by
injection). Natural progesterone is not recorded, as is it
not a prescription medicine.
The proportions of repeat and acute prescriptions were de-
termined for each drug group over the study period. The
proportions could provide an indication of whether the
women perceive the treatment to be efficacious; the great-
er the number of repeat prescriptions, then presumably
the more successful the treatment is perceived as being.
The variation in the ratio of repeat and acute prescriptions
remained consistent across the study period for each
group of drugs apart from diuretics. (The only significant
difference in the number of acute and repeat prescriptions
over time was for the subgroup of diuretics which showed
a significant increase in the number of repeat prescrip-
tions over the study period). However, there was some
Figure 1
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variation in the ratio of acute and repeat prescriptions
when the yearly proportions of acute and repeat prescrip-
tions for the individual drug groups were compared. Fig-
ure 3 shows the proportions of new and repeat
prescriptions for the individual drug groups for 1996. Pre-
scriptions linked to the diagnosis of premenstrual syn-
drome for tricyclic antidepressants were most likely to be
repeated whereas prescriptions for oral contraceptives
were the least likely to be repeated. Figure 3 also shows the
general proportions of acute and repeat prescriptions, tak-
en from reference [22].
Discussion
There is a vast array of suggested treatments for premen-
strual syndrome. The purpose of this study was to look at
the diagnoses and associated prescription rates for the var-
ious medical treatment options for women presenting at
a general practice with premenstrual syndrome
This study has revealed a surprising drop in the number of
prescription-linked diagnoses of premenstrual syndrome.
It is not immediately apparent why fewer women are be-
ing diagnosed with premenstrual syndrome, particularly
as an analysis of the OXMIS code for another menstrual
cycle disorder, heavy bleeding, showed that this diagnosis
has remained relatively constant over the same period. A
possible explanation is the recent increase in popularity of
alternative, non-prescription treatments for premenstrual
syndrome. A survey of medical herbalists in 1998 showed
that the second most commonly treated condition was
premenstrual syndrome [13]. It is therefore feasible that
women are experiencing sufficient relief from these non-
prescription treatments such that they no longer seek
medical intervention.
A recent meta analysis of progesterone and progestogens
has shown that neither treatment is efficacious in the
management of PMS [14], however it is not surprising
that progesterone and progestogens are the most com-
monly prescribed treatment for premenstrual syndrome.
Dalton, who has been largely responsible for premen-
strual syndrome becoming a recognised disorder, has en-
thusiastically advocated progesterone as a successful
treatment for many years [15]. Progesterone is available in
the UK, on prescription, as a pessary or suppository, vagi-
nal gel or injection. Oral micronised progesterone is avail-
able in mainland Europe and the United States but not in
the UK. Progestogens, synthetic analogues of progester-
one, have been developed as oral preparations of proges-
terone. Of the progesterone preparations only Cyclogest®,
(progesterone pessary/suppository) has a license for PMS
in the UK. Dydrogesterone, norethisterone and an ethiny-
loestradiol/levonorgestrel combination (Ovranette®), all
have a license for PMS (Table 2: see Additional File). Me-
droxyprogesterone acetate does not have a licence and is
not recommended for PMS in MIMS, BNF or the drug da-
tasheets and this could account for its low prescription
rate, (less than 3% of the total hormonal prescriptions
(figure 2)), although it has been trialed as a treatment for
premenstrual syndrome [16].
The steady increase in the proportion of prescriptions of
selective serotonin re-uptake inhibitors is in agreement
with an overall increase in the number of prescriptions for
Figure 2
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this type of drug for other indications [17]. We anticipate
this increase to continue as fluoxetine received a license
for the treatment of severe premenstrual syndrome/pre-
menstrual dysphoric disorder in 1999, and a recent meta
analysis has shown it to be a highly effective treatment for
this disorder [18].
It is possible that the sudden drop in vitamin B6 prescrip-
tions from 19% in 1997 to 11% in 1998 results from pro-
posals from the UK Department of Health to restrict the
dosage available because of potential, although reversible,
neurotoxic effects at very high doses [19].
Research into potential treatments for premenstrual syn-
drome has been restricted by the lack of accurate diagnos-
tic techniques of the disorder in the study population. It is
now widely accepted that the diagnosis of premenstrual
syndrome can only be obtained through the structured
evaluation of 1–3 months of prospective symptom re-
cording and with the exclusion of any underlying psychi-
atric or medical disorder. Recent trials for premenstrual
syndrome/premenstrual dysphoric disorder are conduct-
ed using these strict diagnostic criteria and therefore any
reported efficacy can be considered to be proven for a
woman with premenstrual syndrome. In practice this is
not the same population that presents with the complaint
of premenstrual syndrome. It has been estimated that be-
tween 25–75% of women who present with premenstrual
syndrome actually have another medical condition [20].
The lack of suitable, easy to administer, diagnostic tools
mean that virtually all diagnoses of premenstrual syn-
drome are made by self-assessment and up to half of these
self-assessments have been shown to be incorrect [21].
This high level of incorrect assessment coupled with the
known high placebo response [22] has probably resulted
in the widespread use of inappropriate treatments and the
inappropriate licensing of certain treatments. It is interest-
ing that the number of repeat prescriptions for any drug
group is so low in this study. A recent study estimated that
repeat prescriptions generally account for 75% of all pre-
scriptions [23]. The highest proportion of repeat prescrip-
tions in this study was 50%, which was the proportion of
repeat prescriptions for tricyclic antidepressants in 1997.
It is possible that the lack of correct diagnosis and the fail-
Figure 3
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ure to exclude other medical disorders are reflected in a
low number of successful treatments and thus, repeat pre-
scriptions.
An obvious limitation of this study is that premenstrual
syndrome may be entered under a different diagnostic
code to these searched on. There is frequent confusion in
the clinical situation between premenstrual syndrome
and other gynaecological disorders such as, dysmenor-
rhoea and the perimenopause, and in psychological disor-
ders such as depression or anxiety. Similarly, this study
can only reflect on what women are being prescribed and
there is a large amount of evidence to suggest that most
women with premenstrual syndrome will, at least initial-
ly, self-medicate [1,6,8].
Despite the recent concerns surrounding the interpreta-
tion of data from the General Practitioner Research Data-
base [24], it remains a unique resource for providing
information on the number of diagnoses and prescribing
patterns for many disorders including premenstrual syn-
drome. This study has highlighted a dramatic drop in the
number of women being given a diagnosis of premen-
strual syndrome. It has also demonstrated the wide range
of therapeutic techniques, which are currently being used
in the management of this disorder. The development of
effective treatments for premenstrual syndrome has been
hampered by imprecise diagnostic standards, poorly con-
trolled trials and the promotion of therapies which lack
scientific support. We believe that the evidence for all pos-
sible treatment options for premenstrual syndrome
should be assessed by critical appraisal and meta analysis
to permit definitive statements to be made on the most ef-
ficacious management of premenstrual symptoms. Whilst
this statement is true for all disorders, premenstrual syn-
drome treatments in particular highlight the result of pre-
scribing practice based on inappropriate evidence.
Conclusions
• Prescription linked diagnoses of premenstrual syn-
drome fell four fold over the study period (1993–1998)
• Progestagens including progesterone are the most wide-
ly prescribed treatment for premenstrual syndrome
• Vitamin B6 was the second most frequently recorded
prescription in 1993 but prescriptions halved between
1997 and 1998
• Prescriptions for selective serotonin re-uptake inhibitors
increased dramatically between 1993 and 1998 and were
the second most frequently prescribed treatment in 1998
• Significantly more prescriptions for all drug groups were
acute rather than repeat, in contrast to other disorders.
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